We and others have demonstrated that the MCL1/NOXA complex plays a pivotal role in mediating acquired venetoclax resistance in MCL, and that such a resistance can be overcome by concurrent therapy with the MCL1 inhibitor S63845 [106,143,144]. This evidence concerns the gene MCL1 and mantle cell lymphoma.